All updated as on -
The global Rheumatoid Arthritis Market is expected to reach USD 6.8 billion by 2030, at a CAGR of 2.9% during the forecast period 2022 to 2030.
Joint discomfort and swelling are common symptoms of rheumatoid arthritis. Although anyone can contract the disease, the elderly are more likely to succumb to it. Indicators of rheumatoid arthritis include joint pain, stiffness, soreness, and swelling. There is presently no treatment or cure for rheumatoid arthritis. Nonetheless, disease-modifying anti-rheumatic medications (DMARDs), nonsteroidal anti-inflammatory medicines (NSAIDs), corticosteroids, and uric acid therapies are used to effectively regulate the symptoms of rheumatoid arthritis.
The increasing geriatric population, the widespread use of conventional disease-modifying antirheumatic drugs (DMARDs), and public health campaigns to raise awareness of rheumatoid arthritis symptoms all contribute to the expansion of the rheumatoid arthritis drugs market. The availability of quality medications to low- and middle-income families around the world is also a major factor driving the industry. Other factors contributing to the expansion of the market include the development of increasingly complex biologics, rising healthcare spending, and improved purchasing power. There are more persons of retirement age because life expectancy is increasing worldwide. This tendency is good for business because it increases the disease's prevalence and thus the need for treatments on a per capita basis. Recent in vivo investigations in a mouse model of experimental arthritis have shown that the combination effectively mitigates joint deterioration. So, it stands to reason that an anti-IL-17 antibody and TNF inhibitors will be used in the near future. The advent of modern bi-specific antibodies is also expected to boost the market throughout the anticipated time frame.
The global market for rheumatoid arthritis has been split between biopharmaceuticals and pharmaceuticals, according to the type of molecule being targeted. Among them, the biopharmaceutical sector is expected to maintain its leading position and grow at the fastest rate during the forecast period. The market is expected to gain share from its competitor and hold that lead until 2030. Medication is often used initially in the treatment of this illness. Demand is lower for biopharmaceuticals than for traditional medicines because of the latter's superior therapeutic output and ability to alleviate symptoms of sickness. Biopharmaceuticals include both biologics and biosimilars. Biologic drugs are projected to dominate the market for the foreseeable future since doctors prefer them over biosimilars when treating RA.
Report Coverage
Global Rheumatoid Arthritis research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Rheumatoid Arthritis report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Rheumatoid Arthritis competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Rheumatoid Arthritis market players and analyses their core competencies in each global market sub-segments.
The global rheumatoid arthritis market is divided into the prescription and over-the-counter (OTC) sectors on the basis of the sales channel. The over-the-counter sector is expected to remain the largest of these markets. This change resulted from an advance in our understanding of therapeutic options for reversing disease. Over the forecast period, the prescription sector of the rheumatoid arthritis drugs market is expected to grow at the fastest rate. Long-term abuse of RA drugs can lead to drug resistance, therefore it's important for patients with RA to see rheumatologists and stick to prescribed therapy. There aren't many therapy options available without a prescription, either.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Rheumatoid Arthritis market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Rheumatoid Arthritis market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Rheumatoid Arthritis market based on the below-mentioned segments:
Global Rheumatoid Arthritis Market, By Molecule Type
Global Rheumatoid Arthritis market, By Sales Channel
Global Rheumatoid Arthritis market, Regional Analysis
Joint discomfort and swelling are common symptoms of rheumatoid arthritis. Although anyone can contract the disease, the elderly are more likely to succumb to it. Indicators of rheumatoid arthritis include joint pain, stiffness, soreness, and swelling. There is presently no treatment or cure for rheumatoid arthritis. Nonetheless, disease-modifying anti-rheumatic medications (DMARDs), nonsteroidal anti-inflammatory medicines (NSAIDs), corticosteroids, and uric acid therapies are used to effectively regulate the symptoms of rheumatoid arthritis.
The increasing geriatric population, the widespread use of conventional disease-modifying antirheumatic drugs (DMARDs), and public health campaigns to raise awareness of rheumatoid arthritis symptoms all contribute to the expansion of the rheumatoid arthritis drugs market. The availability of quality medications to low- and middle-income families around the world is also a major factor driving the industry. Other factors contributing to the expansion of the market include the development of increasingly complex biologics, rising healthcare spending, and improved purchasing power. There are more persons of retirement age because life expectancy is increasing worldwide. This tendency is good for business because it increases the disease's prevalence and thus the need for treatments on a per capita basis. Recent in vivo investigations in a mouse model of experimental arthritis have shown that the combination effectively mitigates joint deterioration. So, it stands to reason that an anti-IL-17 antibody and TNF inhibitors will be used in the near future. The advent of modern bi-specific antibodies is also expected to boost the market throughout the anticipated time frame.
The global market for rheumatoid arthritis has been split between biopharmaceuticals and pharmaceuticals, according to the type of molecule being targeted. Among them, the biopharmaceutical sector is expected to maintain its leading position and grow at the fastest rate during the forecast period. The market is expected to gain share from its competitor and hold that lead until 2030. Medication is often used initially in the treatment of this illness. Demand is lower for biopharmaceuticals than for traditional medicines because of the latter's superior therapeutic output and ability to alleviate symptoms of sickness. Biopharmaceuticals include both biologics and biosimilars. Biologic drugs are projected to dominate the market for the foreseeable future since doctors prefer them over biosimilars when treating RA.
Report Coverage
Global Rheumatoid Arthritis research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Rheumatoid Arthritis report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Rheumatoid Arthritis competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Rheumatoid Arthritis market players and analyses their core competencies in each global market sub-segments.
The global rheumatoid arthritis market is divided into the prescription and over-the-counter (OTC) sectors on the basis of the sales channel. The over-the-counter sector is expected to remain the largest of these markets. This change resulted from an advance in our understanding of therapeutic options for reversing disease. Over the forecast period, the prescription sector of the rheumatoid arthritis drugs market is expected to grow at the fastest rate. Long-term abuse of RA drugs can lead to drug resistance, therefore it's important for patients with RA to see rheumatologists and stick to prescribed therapy. There aren't many therapy options available without a prescription, either.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Pfizer Inc., Abbvie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH., Merck & Co Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca, Ampio Pharmaceuticals Inc., Lilly |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Rheumatoid Arthritis Market from 2021 to 2030.
- Market Forecast for Rheumatoid Arthritis Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Rheumatoid Arthritis competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Rheumatoid Arthritis
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Rheumatoid Arthritis market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Rheumatoid Arthritis market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- Pfizer Inc.
- Abbvie Inc.
- Novartis AG
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- Merck & Co Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- AstraZeneca
- Ampio Pharmaceuticals Inc.
- Lilly
Primary Target Market
- Market Players of Rheumatoid Arthritis
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Rheumatoid Arthritis market based on the below-mentioned segments:
Global Rheumatoid Arthritis Market, By Molecule Type
- Biopharmaceuticals
- Pharmaceuticals
Global Rheumatoid Arthritis market, By Sales Channel
- Prescription
- OTC
Global Rheumatoid Arthritis market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive rheumatoid arthritis market market research and competitor analysis for your business to help you develop more profound insights into the rheumatoid arthritis market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the rheumatoid arthritis market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.